The Aged Patient with Lung Cancer: Management Recommendations

Vittorina Zagonel, Umberto Tirelli, Diego Serraino, Giovanni Lo Re, Maria Carmela Merola, Maurizio Mascarin, Mauro Gaetano Trovò, Antonino Carbone, Silvio Monfardini

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Elderly patients with lung cancer have not benefited from the therapeutic improvements obtained during the 1980s with younger adults. Potentially operable non—small-cell lung cancers are more common in elderly patients, who are more likely to have localised disease at diagnosis. Even so, elderly patients are rarely treated with surgery. Radiotherapy remains the most frequently adopted tool to treat non—small-cell lung cancer in this age group. Epipodophyllotoxin derivatives constitute the best option for chemotherapy of elderly patients with small-cell lung cancer. When used as single agent regimens, these drugs show the same overall response rate as combination chemotherapy, but with reduced toxicity. Haematopoietic growth factors are used to reduce bone marrow damage following cytotoxic chemotherapy, and may be a promising tool in elderly patients. Special attention should be given to increasing the number of elderly patients with small-cell lung cancer enrolled in phase I and II studies to investigate new agents for the treatment of this tumour.

Original languageEnglish
Pages (from-to)34-46
Number of pages13
JournalDrugs and Aging
Volume4
Issue number1
DOIs
Publication statusPublished - 1994

Fingerprint

Lung Neoplasms
Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
Podophyllotoxin
Drug Therapy
Combination Drug Therapy
Young Adult
Intercellular Signaling Peptides and Proteins
Radiotherapy
Age Groups
Bone Marrow
Therapeutics
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Pharmacology (medical)
  • Pharmacology

Cite this

The Aged Patient with Lung Cancer : Management Recommendations. / Zagonel, Vittorina; Tirelli, Umberto; Serraino, Diego; Re, Giovanni Lo; Merola, Maria Carmela; Mascarin, Maurizio; Trovò, Mauro Gaetano; Carbone, Antonino; Monfardini, Silvio.

In: Drugs and Aging, Vol. 4, No. 1, 1994, p. 34-46.

Research output: Contribution to journalArticle

Zagonel, V, Tirelli, U, Serraino, D, Re, GL, Merola, MC, Mascarin, M, Trovò, MG, Carbone, A & Monfardini, S 1994, 'The Aged Patient with Lung Cancer: Management Recommendations', Drugs and Aging, vol. 4, no. 1, pp. 34-46. https://doi.org/10.2165/00002512-199404010-00004
Zagonel, Vittorina ; Tirelli, Umberto ; Serraino, Diego ; Re, Giovanni Lo ; Merola, Maria Carmela ; Mascarin, Maurizio ; Trovò, Mauro Gaetano ; Carbone, Antonino ; Monfardini, Silvio. / The Aged Patient with Lung Cancer : Management Recommendations. In: Drugs and Aging. 1994 ; Vol. 4, No. 1. pp. 34-46.
@article{48a933b33d4b4fd5adf54a4c576952c3,
title = "The Aged Patient with Lung Cancer: Management Recommendations",
abstract = "Elderly patients with lung cancer have not benefited from the therapeutic improvements obtained during the 1980s with younger adults. Potentially operable non—small-cell lung cancers are more common in elderly patients, who are more likely to have localised disease at diagnosis. Even so, elderly patients are rarely treated with surgery. Radiotherapy remains the most frequently adopted tool to treat non—small-cell lung cancer in this age group. Epipodophyllotoxin derivatives constitute the best option for chemotherapy of elderly patients with small-cell lung cancer. When used as single agent regimens, these drugs show the same overall response rate as combination chemotherapy, but with reduced toxicity. Haematopoietic growth factors are used to reduce bone marrow damage following cytotoxic chemotherapy, and may be a promising tool in elderly patients. Special attention should be given to increasing the number of elderly patients with small-cell lung cancer enrolled in phase I and II studies to investigate new agents for the treatment of this tumour.",
author = "Vittorina Zagonel and Umberto Tirelli and Diego Serraino and Re, {Giovanni Lo} and Merola, {Maria Carmela} and Maurizio Mascarin and Trov{\`o}, {Mauro Gaetano} and Antonino Carbone and Silvio Monfardini",
year = "1994",
doi = "10.2165/00002512-199404010-00004",
language = "English",
volume = "4",
pages = "34--46",
journal = "Drugs and Aging",
issn = "1170-229X",
publisher = "Springer International Publishing",
number = "1",

}

TY - JOUR

T1 - The Aged Patient with Lung Cancer

T2 - Management Recommendations

AU - Zagonel, Vittorina

AU - Tirelli, Umberto

AU - Serraino, Diego

AU - Re, Giovanni Lo

AU - Merola, Maria Carmela

AU - Mascarin, Maurizio

AU - Trovò, Mauro Gaetano

AU - Carbone, Antonino

AU - Monfardini, Silvio

PY - 1994

Y1 - 1994

N2 - Elderly patients with lung cancer have not benefited from the therapeutic improvements obtained during the 1980s with younger adults. Potentially operable non—small-cell lung cancers are more common in elderly patients, who are more likely to have localised disease at diagnosis. Even so, elderly patients are rarely treated with surgery. Radiotherapy remains the most frequently adopted tool to treat non—small-cell lung cancer in this age group. Epipodophyllotoxin derivatives constitute the best option for chemotherapy of elderly patients with small-cell lung cancer. When used as single agent regimens, these drugs show the same overall response rate as combination chemotherapy, but with reduced toxicity. Haematopoietic growth factors are used to reduce bone marrow damage following cytotoxic chemotherapy, and may be a promising tool in elderly patients. Special attention should be given to increasing the number of elderly patients with small-cell lung cancer enrolled in phase I and II studies to investigate new agents for the treatment of this tumour.

AB - Elderly patients with lung cancer have not benefited from the therapeutic improvements obtained during the 1980s with younger adults. Potentially operable non—small-cell lung cancers are more common in elderly patients, who are more likely to have localised disease at diagnosis. Even so, elderly patients are rarely treated with surgery. Radiotherapy remains the most frequently adopted tool to treat non—small-cell lung cancer in this age group. Epipodophyllotoxin derivatives constitute the best option for chemotherapy of elderly patients with small-cell lung cancer. When used as single agent regimens, these drugs show the same overall response rate as combination chemotherapy, but with reduced toxicity. Haematopoietic growth factors are used to reduce bone marrow damage following cytotoxic chemotherapy, and may be a promising tool in elderly patients. Special attention should be given to increasing the number of elderly patients with small-cell lung cancer enrolled in phase I and II studies to investigate new agents for the treatment of this tumour.

UR - http://www.scopus.com/inward/record.url?scp=0028083410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028083410&partnerID=8YFLogxK

U2 - 10.2165/00002512-199404010-00004

DO - 10.2165/00002512-199404010-00004

M3 - Article

C2 - 8130381

AN - SCOPUS:0028083410

VL - 4

SP - 34

EP - 46

JO - Drugs and Aging

JF - Drugs and Aging

SN - 1170-229X

IS - 1

ER -